| Today’s Big NewsFeb 3, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By James Waldron AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. |
|
|
|
By James Waldron Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.” |
By James Waldron Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. |
By Nick Paul Taylor Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not been able to fully capitalize” on the asset’s potential. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Fraiser Kansteiner With President Donald Trump’s tariffs now in place, industry groups are warning that the move could hamstring U.S. pharmaceutical supplies and productivity. |
By Emma Beavins Sen. Bill Cassidy, chair of the Senate HELP Committee, and ranking member Bernie Sanders were aligned on their concerns about RFK Jr.'s approach to vaccines. With a vote on RFK Jr.’s nomination to take place in the Senate Finance Committee next week, Cassidy, who also sits on that committee, said he’s going to have to use the weekend to make up his mind. |
By Darren Incorvaia A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo. A new study found that injecting the molecule into mice with the autoimmune disease slowed the rate of the rodents’ pigment loss and boosted the amount of pigment-protecting T cells. |
By Angus Liu Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in positive trial results that could set it up for a full approval. |
By Heather Landi The Trump administration indefinitely canceled meetings of the HITAC, an advisory panel established by the 21st Century Cures Act that helps the federal government establish rules and standards for the use of healthcare data and technologies. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
